Nothing Special   »   [go: up one dir, main page]

WO2003044056A3 - Chemically-modified human growth hormone conjugates - Google Patents

Chemically-modified human growth hormone conjugates Download PDF

Info

Publication number
WO2003044056A3
WO2003044056A3 PCT/US2002/037270 US0237270W WO03044056A3 WO 2003044056 A3 WO2003044056 A3 WO 2003044056A3 US 0237270 W US0237270 W US 0237270W WO 03044056 A3 WO03044056 A3 WO 03044056A3
Authority
WO
WIPO (PCT)
Prior art keywords
chemically
growth hormone
human growth
modified human
hgh
Prior art date
Application number
PCT/US2002/037270
Other languages
French (fr)
Other versions
WO2003044056A2 (en
Inventor
Rory F Box
Wei Lao
Ned R Siegel
Original Assignee
Pharmacia Corp
Rory F Box
Wei Lao
Ned R Siegel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CA002467731A priority Critical patent/CA2467731A1/en
Priority to MXPA04004809A priority patent/MXPA04004809A/en
Priority to AU2002356990A priority patent/AU2002356990A1/en
Priority to EP02803695A priority patent/EP1453859A2/en
Priority to APAP/P/2004/003050A priority patent/AP2004003050A0/en
Priority to BRPI0214451-4A priority patent/BR0214451A/en
Priority to EA200400565A priority patent/EA008505B1/en
Priority to HU0500997A priority patent/HUP0500997A2/en
Application filed by Pharmacia Corp, Rory F Box, Wei Lao, Ned R Siegel filed Critical Pharmacia Corp
Priority to JP2003545691A priority patent/JP2005525302A/en
Priority to IL16203102A priority patent/IL162031A0/en
Priority to YU53104A priority patent/RS53104A/en
Publication of WO2003044056A2 publication Critical patent/WO2003044056A2/en
Publication of WO2003044056A3 publication Critical patent/WO2003044056A3/en
Priority to IS7268A priority patent/IS7268A/en
Priority to HR20040448A priority patent/HRP20040448A2/en
Priority to TNP2004000090A priority patent/TNSN04090A1/en
Priority to NO20042182A priority patent/NO20042182L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention provides a chemically modified human Growth Hormone (hGH) prepared by binding a water soluble polymer to the protein. The chemically-modified protein according to the present invention may have a much longer lasting hGH activity than that of the unmodified hGH, enabling reduced dose and scheduling opportunities.
PCT/US2002/037270 2001-11-20 2002-11-20 Chemically-modified human growth hormone conjugates WO2003044056A2 (en)

Priority Applications (15)

Application Number Priority Date Filing Date Title
JP2003545691A JP2005525302A (en) 2001-11-20 2002-11-20 Chemically modified human growth hormone conjugates
MXPA04004809A MXPA04004809A (en) 2001-11-20 2002-11-20 Chemically-modified human growth hormone conjugates.
IL16203102A IL162031A0 (en) 2001-11-20 2002-11-20 Chemically-modified human growth hormone conjugates
APAP/P/2004/003050A AP2004003050A0 (en) 2001-11-20 2002-11-20 Chemically modified human growth hormone conjugates
BRPI0214451-4A BR0214451A (en) 2001-11-20 2002-11-20 chemically modified human growth hormone conjugates
EA200400565A EA008505B1 (en) 2001-11-20 2002-11-20 Chemically modified human growth hormone conjugates
HU0500997A HUP0500997A2 (en) 2001-11-20 2002-11-20 Chemically-modified human growth hormone conjugates
CA002467731A CA2467731A1 (en) 2001-11-20 2002-11-20 Chemically-modified human growth hormone conjugates
AU2002356990A AU2002356990A1 (en) 2001-11-20 2002-11-20 Chemically-modified human growth hormone conjugates
EP02803695A EP1453859A2 (en) 2001-11-20 2002-11-20 Chemically-modified human growth hormone conjugates
YU53104A RS53104A (en) 2001-11-20 2002-11-20 Chemically-modified human growth hormone conjugates
IS7268A IS7268A (en) 2001-11-20 2004-05-17 Chemically altered synthetic human growth hormone
HR20040448A HRP20040448A2 (en) 2001-11-20 2004-05-20 Method for detecting cells with numerical chromosomal abnormalities
TNP2004000090A TNSN04090A1 (en) 2001-11-20 2004-05-20 CHEMICALLY MODIFIED HUMAN GROWTH HORMONE CONJUGATES
NO20042182A NO20042182L (en) 2001-11-20 2004-05-26 Chemically modified growth hormone conjugates

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33190701P 2001-11-20 2001-11-20
US60/331,907 2001-11-20

Publications (2)

Publication Number Publication Date
WO2003044056A2 WO2003044056A2 (en) 2003-05-30
WO2003044056A3 true WO2003044056A3 (en) 2003-08-21

Family

ID=23295870

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/037270 WO2003044056A2 (en) 2001-11-20 2002-11-20 Chemically-modified human growth hormone conjugates

Country Status (25)

Country Link
EP (1) EP1453859A2 (en)
JP (2) JP2005525302A (en)
KR (2) KR20050044858A (en)
CN (1) CN1608079A (en)
AP (1) AP2004003050A0 (en)
AU (1) AU2002356990A1 (en)
BR (1) BR0214451A (en)
CA (1) CA2467731A1 (en)
CO (1) CO5580794A2 (en)
EA (2) EA200700431A1 (en)
EC (1) ECSP045114A (en)
GE (1) GEP20063860B (en)
HR (1) HRP20040448A2 (en)
HU (1) HUP0500997A2 (en)
IL (1) IL162031A0 (en)
IS (1) IS7268A (en)
MA (1) MA27544A1 (en)
MX (1) MXPA04004809A (en)
NO (1) NO20042182L (en)
OA (1) OA13063A (en)
PL (1) PL374354A1 (en)
RS (1) RS53104A (en)
TN (1) TNSN04090A1 (en)
WO (1) WO2003044056A2 (en)
ZA (1) ZA200403907B (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104803865A (en) * 2004-12-22 2015-07-29 Ambrx公司 Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
US12133883B2 (en) 2014-11-18 2024-11-05 Ascendis Pharma Endocrinology Division A/S Polymeric hGH prodrugs

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030171285A1 (en) * 2001-11-20 2003-09-11 Finn Rory F. Chemically-modified human growth hormone conjugates
EP1507755A4 (en) * 2001-12-11 2006-05-17 Sun Bio Inc Novel monofunctional polyethylene glycol aldehydes
US6916962B2 (en) 2001-12-11 2005-07-12 Sun Bio, Inc. Monofunctional polyethylene glycol aldehydes
US7041855B2 (en) 2001-12-11 2006-05-09 Sun Bio, Inc. Monofunctional polyethylene glycol aldehydes
US6956135B2 (en) 2001-12-11 2005-10-18 Sun Bio, Inc. Monofunctional polyethylene glycol aldehydes
JP2005526151A (en) * 2002-01-18 2005-09-02 バイオゲン アイデック エムエー インク． Polyalkylene glycols having moieties for the binding of biologically active compounds
EP1591467A1 (en) * 2002-09-09 2005-11-02 Nektar Therapeutics Al, Corporation Conjugate between a polyethylene glycol having a terminal alkanal group and a human growth hormone
KR20050093856A (en) 2002-09-09 2005-09-23 넥타르 테라퓨틱스 에이엘, 코포레이션 Water-soluble polymer alkanals
US20040142870A1 (en) * 2002-11-20 2004-07-22 Finn Rory F. N-terminally monopegylated human growth hormone conjugates, process for their preparation, and methods of use thereof
US20050281778A1 (en) * 2003-03-28 2005-12-22 Myung-Ok Park Human growth hormone conjugated with biocompatible polymer
ES2349743T3 (en) * 2003-10-10 2011-01-11 Novo Nordisk A/S DERIVATIVES OF IL-21.
US7524813B2 (en) 2003-10-10 2009-04-28 Novo Nordisk Health Care Ag Selectively conjugated peptides and methods of making the same
CA2552043A1 (en) * 2004-01-21 2005-08-04 Novo Nordisk A/S Transglutaminase mediated conjugation of peptides
AU2005278903A1 (en) * 2004-08-31 2006-03-09 Pharmacia & Upjohn Company Llc Glycerol branched polyethylene glycol human growth hormone conjugates, process for their preparation, and methods of use thereof
NZ584597A (en) 2004-12-22 2011-09-30 Ambrx Inc Modified human growth hormone
EP1836316A4 (en) * 2004-12-22 2009-07-22 Ambrx Inc Methods for expression and purification of recombinant human growth hormone
US20090105134A1 (en) 2005-02-10 2009-04-23 Novo Nordisk A/S C-Terminally Pegylated Growth Hormones
ATE497975T1 (en) 2005-04-18 2011-02-15 Novo Nordisk As IL-21 VARIANTS
RU2008105545A (en) 2005-08-30 2009-10-10 Ново Нордиск Хелс Кеа Аг (Ch) LIQUID DRUGS OF PEGLIATED GROWTH HORMONE
NZ567234A (en) * 2005-11-08 2011-09-30 Ambrx Inc Accelerants for the modification of non-natural amino acids and non-natural amino acid polypeptides
NZ595303A (en) * 2005-12-14 2013-03-28 Ambrx Inc Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
RU2009103198A (en) 2006-07-07 2010-08-20 Ново Нордиск Хелс Кеа Аг (Ch) NEW PROTEIN CONJUGATES AND METHODS FOR PRODUCING THEM
CN101108895B (en) * 2006-07-19 2011-10-26 北京键凯科技有限公司 Polyglycol ethanal derivant and combo of medicament and the same
WO2008049920A2 (en) 2006-10-26 2008-05-02 Novo Nordisk A/S Il-21 variants
CL2008002399A1 (en) * 2007-08-16 2009-01-02 Pharmaessentia Corp Substantially pure conjugate having a polymeric portion, a protein portion (interferon alpha 2b) and an aliphatic binder of 1 to 10 carbon atoms, useful in the treatment of hepatitis b or c.
DK2272875T3 (en) * 2008-04-03 2014-03-31 Biosteed Gene Expression Tech Co Ltd Double-stranded polyethylene glycol-modified growth hormone, method of preparation and use thereof
KR101104574B1 (en) * 2008-05-14 2012-01-11 성균관대학교산학협력단 Human growth hormone derivative linked with polyethyleneglycol, method for the preparation thereof and pharmaceutical composition comprising the same
MX2011001167A (en) * 2008-07-31 2011-04-12 Pharmaessentia Corp Peptide-polymer conjugates.
RU2526804C2 (en) 2008-08-06 2014-08-27 Ново Нордиск Хелс Кеа Аг Conjugated proteins with prolonged action in vivo
RU2409669C9 (en) * 2008-08-18 2012-05-27 ООО "Саентифик Фьючер Менеджмент" ("Scientific Future Management", "SFM") Method for immobilising biologically active substance (bas) on carrier (versions) and bas-carrier conjugate produced by such methods
WO2010030366A2 (en) * 2008-09-11 2010-03-18 Nektar Therapeutics Polymeric alpha-hydroxy aldehyde and ketone reagents and conjugation method
RU2539797C2 (en) 2009-01-22 2015-01-27 Ново Нордиск Хелс Кеа Аг Human growth hormone derivative highly resistant to proteolytic degradation, method for preparing this derivative, using it, method of treating, and pharmaceutical composition
CN105963710A (en) 2009-08-06 2016-09-28 诺沃—诺迪斯克保健股份有限公司 Growth hormones with prolonged in-vivo efficacy
HUE038405T2 (en) 2009-12-15 2018-10-29 Ascendis Pharma Endocrinology Div A/S Dry growth hormone composition transiently linked to a polymer carrier
US9695226B2 (en) 2010-01-22 2017-07-04 Novo Nordisk Healthcare Ag Growth hormones with prolonged in-vivo efficacy
CA2787895A1 (en) 2010-01-22 2011-07-28 Novo Nordisk Health Care Ag Stable growth hormone compounds
KR20130115086A (en) * 2010-05-17 2013-10-21 세빅스 인코포레이티드 Pegylated c-peptide
EP2446898A1 (en) 2010-09-30 2012-05-02 Laboratorios Del. Dr. Esteve, S.A. Use of growth hormone to enhance the immune response in immunosuppressed patients
EA019967B1 (en) * 2011-12-21 2014-07-30 Общество С Ограниченной Ответственностью "Форт" (Ооо "Форт") Polyethyleneglycol covalent conjugate with human growth hormone
JP6464145B2 (en) 2013-04-05 2019-02-06 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー Growth hormone compound preparation
NZ730924A (en) 2014-11-06 2022-04-29 Pharmaessentia Corp Dosage regimen for pegylated interferon
WO2016079302A1 (en) 2014-11-21 2016-05-26 Ascendis Pharma Growth Disorders Division A/S Long-acting growth hormone dosage forms
MA41957A (en) * 2015-03-11 2018-02-28 Nektar Therapeutics CONJUGATES OF A FRACTION OF IL-7 AND A POLYMER
US10842879B2 (en) * 2015-09-18 2020-11-24 University Of Miyazaki Long-acting adrenomedullin derivative
CN114539384B (en) * 2020-11-19 2024-09-06 江苏众红生物工程创药研究院有限公司 Pegylated long-acting growth hormone, preparation method and medical application thereof

Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
WO1989005824A1 (en) * 1987-12-23 1989-06-29 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides to facilitate covalent linkages to a hydrophilic moiety
EP0458064A2 (en) * 1990-05-04 1991-11-27 American Cyanamid Company Stabilization of somatotropins and other proteins by modification of cysteine residues
WO1992016555A1 (en) * 1991-03-18 1992-10-01 Enzon, Inc. Hydrazine containing conjugates of polypeptides and glycopolypeptides with polymers
WO1993000109A1 (en) * 1991-06-28 1993-01-07 Genentech, Inc. Method of stimulating immune response using growth hormone
EP0605963A2 (en) * 1992-12-09 1994-07-13 Ortho Pharmaceutical Corporation Peg hydrazone and peg oxime linkage forming reagents and protein derivatives thereof
WO1996011953A1 (en) * 1994-10-12 1996-04-25 Amgen Inc. N-terminally chemically modified protein compositions and methods
WO1997011178A1 (en) * 1995-09-21 1997-03-27 Genentech, Inc. Human growth hormone variants
WO1999003887A1 (en) * 1997-07-14 1999-01-28 Bolder Biotechnology, Inc. Derivatives of growth hormone and related proteins
WO2000042175A1 (en) * 1999-01-14 2000-07-20 Bolder Biotechnology Inc. Methods for making proteins containing free cysteine residues
WO2000044785A1 (en) * 1999-01-29 2000-08-03 F. Hoffmann-La Roche Ag Gcsf conjugates
WO2001076639A2 (en) * 2000-04-06 2001-10-18 Pharmacia Corporation Chemically-modified myelopoietin conjugates
WO2002055532A2 (en) * 2001-01-11 2002-07-18 Maxygen Aps Variant growth hormone molecules conjugated with macromolecular compounds

Patent Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
WO1989005824A1 (en) * 1987-12-23 1989-06-29 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides to facilitate covalent linkages to a hydrophilic moiety
EP0458064A2 (en) * 1990-05-04 1991-11-27 American Cyanamid Company Stabilization of somatotropins and other proteins by modification of cysteine residues
WO1992016555A1 (en) * 1991-03-18 1992-10-01 Enzon, Inc. Hydrazine containing conjugates of polypeptides and glycopolypeptides with polymers
WO1993000109A1 (en) * 1991-06-28 1993-01-07 Genentech, Inc. Method of stimulating immune response using growth hormone
EP0605963A2 (en) * 1992-12-09 1994-07-13 Ortho Pharmaceutical Corporation Peg hydrazone and peg oxime linkage forming reagents and protein derivatives thereof
WO1996011953A1 (en) * 1994-10-12 1996-04-25 Amgen Inc. N-terminally chemically modified protein compositions and methods
WO1997011178A1 (en) * 1995-09-21 1997-03-27 Genentech, Inc. Human growth hormone variants
WO1999003887A1 (en) * 1997-07-14 1999-01-28 Bolder Biotechnology, Inc. Derivatives of growth hormone and related proteins
WO2000042175A1 (en) * 1999-01-14 2000-07-20 Bolder Biotechnology Inc. Methods for making proteins containing free cysteine residues
WO2000044785A1 (en) * 1999-01-29 2000-08-03 F. Hoffmann-La Roche Ag Gcsf conjugates
WO2001076639A2 (en) * 2000-04-06 2001-10-18 Pharmacia Corporation Chemically-modified myelopoietin conjugates
WO2002055532A2 (en) * 2001-01-11 2002-07-18 Maxygen Aps Variant growth hormone molecules conjugated with macromolecular compounds

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
CLARK R ET AL: "Long-acting growth hormones produced by conjugation with polyethylene glycol", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, vol. 271, no. 36, 6 September 1996 (1996-09-06), pages 21969 - 21977, XP002216386, ISSN: 0021-9258 *
FELIX A M ET AL: "PEGYLATED PEPTIDES IV ENHANCED BIOLOGICAL ACTIVITY OF SITE-DIRECTED PEGYLATED GRF ANALOGS", INTERNATIONAL JOURNAL OF PEPTIDE AND PROTEIN RESEARCH, MUNKSGAARD, COPENHAGEN, DK, vol. 46, no. 3/4, 1 September 1995 (1995-09-01), pages 253 - 264, XP000526320, ISSN: 0367-8377 *
MONFARDINI C ET AL: "A BRANCHED MONOMETHOXYPOLY(ETHYLENE GLYCOL) FOR PROTEIN MODIFICATION", BIOCONJUGATE CHEMISTRY, AMERICAN CHEMICAL SOCIETY, WASHINGTON, US, vol. 6, no. 1, 1995, pages 62 - 69, XP000494804, ISSN: 1043-1802 *
THORNER MICHAEL O ET AL: "Growth hormone (GH) receptor blockade with a PEG-modified GH (B2036-PEG) lowers serum insulin-like growth factor-I but does not acutely stimulate serum GH.", JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, vol. 84, no. 6, June 1999 (1999-06-01), pages 2098 - 2103, XP002237939, ISSN: 0021-972X *
VERONESE FRANCESCO M: "Peptide and protein PEGylation: A review of problems and solutions.", BIOMATERIALS, vol. 22, no. 5, March 2001 (2001-03-01), pages 405 - 417, XP002237938, ISSN: 0142-9612 *
ZALIPSKY S: "FUNCTIONALIZED POLY(ETHYLENE GLYCOL) FOR PREPARATION OF BIOLOGICALLY RELEVANT CONJUGATES", BIOCONJUGATE CHEMISTRY, AMERICAN CHEMICAL SOCIETY, WASHINGTON, US, vol. 6, no. 2, 1995, pages 150 - 165, XP002068523, ISSN: 1043-1802 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104803865A (en) * 2004-12-22 2015-07-29 Ambrx公司 Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
US12133883B2 (en) 2014-11-18 2024-11-05 Ascendis Pharma Endocrinology Division A/S Polymeric hGH prodrugs

Also Published As

Publication number Publication date
HRP20040448A2 (en) 2006-02-28
CO5580794A2 (en) 2005-11-30
IL162031A0 (en) 2005-11-20
IS7268A (en) 2004-05-17
PL374354A1 (en) 2005-10-17
EA200700431A1 (en) 2008-02-28
JP2005525302A (en) 2005-08-25
KR20070072924A (en) 2007-07-06
KR20050044858A (en) 2005-05-13
ZA200403907B (en) 2007-12-27
CA2467731A1 (en) 2003-05-30
AU2002356990A1 (en) 2003-06-10
HUP0500997A2 (en) 2007-11-28
EA008505B1 (en) 2007-06-29
AP2004003050A0 (en) 2004-06-30
BR0214451A (en) 2006-05-30
CN1608079A (en) 2005-04-20
EP1453859A2 (en) 2004-09-08
ECSP045114A (en) 2004-07-23
MA27544A1 (en) 2005-10-03
EA200400565A1 (en) 2005-06-30
RS53104A (en) 2006-10-27
WO2003044056A2 (en) 2003-05-30
NO20042182L (en) 2004-08-11
JP2006321808A (en) 2006-11-30
GEP20063860B (en) 2006-06-26
MXPA04004809A (en) 2004-08-11
TNSN04090A1 (en) 2006-06-01
OA13063A (en) 2006-11-10

Similar Documents

Publication Publication Date Title
WO2003044056A3 (en) Chemically-modified human growth hormone conjugates
WO2005000359A3 (en) Chemically-modified human growth hormone conjugates
WO2002057293A3 (en) Modified zinc finger binding proteins
WO2009133137A3 (en) Pegylated recombinant human growth hormone compounds
NO20063926L (en) N-terminal monopegylated human growth hormone conjugates, methods of preparation and use thereof
WO2003018636A3 (en) Chimaeric peptides of insulin, their compositions and use in treating diabetes
WO2002099084A3 (en) Composite binding polypeptides
WO2002062844A3 (en) Long lasting growth hormone releasing factor derivatives
WO2004020405A3 (en) Modified transferrin fusion proteins
WO2006071840A8 (en) Formulations of human growth hormone comprising a non-naturally encoded amino acid
WO2003020932A1 (en) Novel secretory proteins and dna thereof
EP2284191A3 (en) Process for the preparation of hGH
WO2001078683A3 (en) Sustained release formulations comprising growth hormone
WO2002039998A3 (en) Methods and compositions for regulating memory consolidation
AU2002314825A1 (en) Anti-p40 immunoglobulin derived proteins, compositions, methods and uses
EP2107071A3 (en) Anti-EpCAM immunoglobulins
WO2001076639A3 (en) Chemically-modified myelopoietin conjugates
WO2003000179A3 (en) Chemically-modified progenipoietin conjugates
AU2002365269A1 (en) Mut-il-18 or mut-il-18r proteins, antibodies, compositions, methods and uses
WO2003020759A3 (en) A caspase- 8 binding protein, its preparation and use
WO2002099438A3 (en) Modulation of steroid hormone uptake
WO2003057712A3 (en) Humanized lactoferrin and uses thereof
WO2002068614A3 (en) Interferon regulatory factor-1/human estrogen receptor fusion protein and its use for treating carcinomas
TW200517125A (en) Pharmaceutical composition for treatment of solid cancers
WO2005075021A3 (en) Chemically-modified human growth hormone receptor antagonist conjugates

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: P-531/04

Country of ref document: YU

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2467731

Country of ref document: CA

Ref document number: 162031

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2002356990

Country of ref document: AU

Ref document number: 533021

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2004/03907

Country of ref document: ZA

Ref document number: P20040448A

Country of ref document: HR

Ref document number: PA/a/2004/004809

Country of ref document: MX

Ref document number: 374354

Country of ref document: PL

Ref document number: 04046633

Country of ref document: CO

Ref document number: 1366/DELNP/2004

Country of ref document: IN

Ref document number: 1200400464

Country of ref document: VN

Ref document number: 2003545691

Country of ref document: JP

Ref document number: 200403907

Country of ref document: ZA

Ref document number: 1020047007708

Country of ref document: KR

Ref document number: 200400565

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 1-2004-500731

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 8241

Country of ref document: GE

Ref document number: 5599

Country of ref document: GE

WWE Wipo information: entry into national phase

Ref document number: 2002803695

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 20028259289

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2002803695

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: DZP2004000133

Country of ref document: DZ

ENP Entry into the national phase

Ref document number: PI0214451

Country of ref document: BR

WWE Wipo information: entry into national phase

Ref document number: 1020077011730

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 12007501501

Country of ref document: PH

Ref document number: 12007501500

Country of ref document: PH

WWW Wipo information: withdrawn in national office

Ref document number: 2002803695

Country of ref document: EP